Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472869 | 0.91 | MAPT (0.45) | CHRM1EPHX1GAAMAPTEPHX2 | |
| SCHEMBL21597906 | 0.86 | CHRM1 (0.49) | CHRM1EPHX1GAAMAPTEPHX2 | |
| SCHEMBL22472884 | 0.84 | CHRM1 (0.46) | CHRM1GAAEPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14978890 | 0.80 | CHRM1 (0.65) | CHRM1EPHX1GAAMAPTL3MBTL1 | |
| SCHEMBL22472944 | 0.79 | CHRM1 (0.67) | CHRM1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14978899 | 0.77 | CHRM1 (0.65) | CHRM1EPHX1GAAMAPTL3MBTL1 | |
| SCHEMBL22472868 | 0.76 | MAPT (0.43) | CHRM1EPHX1GAAMAPTEPHX2 | |
| SCHEMBL22472905 | 0.76 | ALDH1A1 (0.53) | CHRM1MAPTL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL14978908 | 0.76 | CHRM1 (0.66) | CHRM1GAAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL15630428 | 0.75 | CHRM4 (0.49) | CHRM1EPHX1GAAMAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885EPHX1 978/4885GAA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.